acute ischemic stroke
Conditions
Interventions
Experimental group:basic treatment+dl-3-n-butylphthalide injection 100ml, bid, 10d+dl-3-n-butylphthalide soft capsule 200mg, tid, 90d
control group:basic treatment
Sponsors
Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. first onset or history of stroke with mRSs=1, cerebral infarction in internal carotid artery system within 72h; 2. cerebral hemorrhage excluded by CT; 3. aged 18-80 years; 4. clear signs of nervous system orientation, NIHSS=20 (including minor stroke) 5. patients accepted clinical trial and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. diagnosed intracranial hemorrhagic by CT or suffering diseases with bleeding tendency; 2. cerebral infarction in vertebral basilar artery system; 3. liver dysfunction (aminotransferase exceeded the upper limit of the normal value of 1.5 times), renal dysfunction (Cr>2.0mg/dl or 177 µmol/L) or other severe systemic diseases, etc.; 4. concurrent malignancy or ongoing anti-tumor therapy; 5. allergic constitution, allergic to celery or dl-3-n-butylphthalide; 6. pregnant or lactating women; 7. Patients with dementia or mental disorders, or not considered suitable for this clinical study; 8. participating or participated in other clinical intervention studies within 90 days before receiving the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rLMC;CBF;CBV;MTT;TTP; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS;MMSE; | — |
Countries
China
Contacts
Public ContactYUN XU
Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing
Outcome results
None listed